205 related articles for article (PubMed ID: 31324092)
21. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
[No Abstract] [Full Text] [Related]
22. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
[TBL] [Abstract][Full Text] [Related]
23. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
24. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
[TBL] [Abstract][Full Text] [Related]
25. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
[TBL] [Abstract][Full Text] [Related]
26. Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Prescrire Int; 2017 Apr; 26(181):89-92. PubMed ID: 30730656
[No Abstract] [Full Text] [Related]
27. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Seung KJ; Khan P; Franke MF; Ahmed S; Aiylchiev S; Alam M; Putri FA; Bastard M; Docteur W; Gottlieb G; Hewison C; Islam S; Khachatryan N; Kotrikadze T; Khan U; Kumsa A; Lecca L; Tassew YM; Melikyan N; Naing YY; Oyewusi L; Rich M; Wanjala S; Yedilbayev A; Huerga H; Mitnick CD
Clin Infect Dis; 2020 Jul; 71(2):415-418. PubMed ID: 31676905
[TBL] [Abstract][Full Text] [Related]
28. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Hafkin J; Hittel N; Martin A; Gupta R
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
[No Abstract] [Full Text] [Related]
29. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
30. Delamanid or pretomanid? A Solomonic judgement!
Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
Zhang Q; Liu Y; Tang S; Sha W; Xiao H
Cell Biochem Biophys; 2013; 67(3):957-63. PubMed ID: 23546935
[TBL] [Abstract][Full Text] [Related]
32. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
33. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
Hu M; Zheng C; Gao F
Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
Hwang H; Kang H; Kwon YS; Jeon D; Shim TS; Yim JJ
Clin Infect Dis; 2021 Oct; 73(8):1362-1369. PubMed ID: 33837767
[TBL] [Abstract][Full Text] [Related]
35. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
36. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
Kuksa L; Barkane L; Hittel N; Gupta R
Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
[No Abstract] [Full Text] [Related]
37. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
38. Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
Ghosh S; Breitscheidel L; Lazarevic N; Martin A; Hafkin J; Hittel N
Eur Respir J; 2021 May; 57(5):. PubMed ID: 33243846
[TBL] [Abstract][Full Text] [Related]
39. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
40. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
